1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
Posted on Thursday, Dec 10, 2009

Australian Company to Conduct Clinical Trial on Mesothelioma Drug

Another new mesothelioma drug clinical trial is slated to begin in December 2009. Australian drug maker Bionomics Ltd plans to conduct a Phase II clinical trial of its anti-cancer drug BNC105. They will conduct the tests on 60 mesothelioma patients in Australia.

The drug has shown great promise thus far by killing cancer cells when testing with solid tumors in animals. Bionomics believes patients will not become resistant to this drug as often happens with other chemotherapy treatments. BNC105 will also undergo a Phase II trial in the United States for the treatment of renal cancer.

The primary goal of this study is to determine the safety and maximum tolerated dose of BNC105 in patients with advanced solid tumors. Bionomics says BNC105 “can extend the life of people suffering from mesothelioma and provide them with a better quality of life.”

Sources:
Bionomics Clinical Trials
The Sydney Morning Herald